Recombinant Adenovirus Serotype 26 (Ad26) and Ad35 Vaccine Vectors Bypass Immunity to Ad5 and Protect Nonhuman Primates against Ebolavirus Challenge

ABSTRACT The use of adenoviruses (Ad) as vaccine vectors against a variety of pathogens has demonstrated their capacity to elicit strong antibody and cell-mediated immune responses. Adenovirus serotype C vectors, such as Ad serotype 5 (Ad5), expressing Ebolavirus (EBOV) glycoprotein (GP), protect completely after a single inoculation at a dose of 1010 viral particles. However, the clinical application of a vaccine based on Ad5 vectors may be hampered, since impairment of Ad5 vaccine efficacy has been demonstrated for humans and nonhuman primates with high levels of preexisting immunity to the vector. Ad26 and Ad35 segregate genetically from Ad5 and exhibit lower seroprevalence in humans, making them attractive vaccine vector alternatives. In the series of studies presented, we show that Ad26 and Ad35 vectors generate robust antigen-specific cell-mediated and humoral immune responses against EBOV GP and that Ad5 immune status does not affect the generation of GP-specific immune responses by these vaccines. We demonstrate partial protection against EBOV by a single-shot Ad26 vaccine and complete protection when this vaccine is boosted by Ad35 1 month later. Increases in efficacy are paralleled by substantial increases in T- and B-cell responses to EBOV GP. These results suggest that Ad26 and Ad35 vectors warrant further development as candidate vaccines for EBOV.

[1]  J. Mascola,et al.  A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. , 2010, Vaccine.

[2]  H. Feldmann,et al.  Prospects for immunisation against Marburg and Ebola viruses , 2010, Reviews in medical virology.

[3]  M. McElrath,et al.  Safety and Immunogenicity of a Replication-Defective Adenovirus Type 5 HIV Vaccine in Ad5-Seronegative Persons: A Randomized Clinical Trial (HVTN 054) , 2010, PloS one.

[4]  Kylie M. Quinn,et al.  CD8+ T Cell Responses following Replication-Defective Adenovirus Serotype 5 Immunization Are Dependent on CD11c+ Dendritic Cells but Show Redundancy in Their Requirement of TLR and Nucleotide-Binding Oligomerization Domain-Like Receptor Signaling , 2010, The Journal of Immunology.

[5]  R. Koup,et al.  Vector Choice Determines Immunogenicity and Potency of Genetic Vaccines against Angola Marburg Virus in Nonhuman Primates , 2010, Journal of Virology.

[6]  Eric Tsao,et al.  Stabilizing formulations for inhalable powders of an adenovirus 35-vectored tuberculosis (TB) vaccine (AERAS-402). , 2010, Vaccine.

[7]  M. Hoelscher,et al.  A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172). , 2010, The Journal of infectious diseases.

[8]  Laurie Lamoreaux,et al.  Priming Immunization with DNA Augments Immunogenicity of Recombinant Adenoviral Vectors for Both HIV-1 Specific Antibody and T-Cell Responses , 2010, PloS one.

[9]  N. Wolfe,et al.  International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. , 2010, Vaccine.

[10]  A. Folgori,et al.  Prime-boost vectored malaria vaccines: Progress and prospects , 2010, Human vaccines.

[11]  J. Kublin,et al.  Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimens. , 2010, The Journal of infectious diseases.

[12]  S. Santra,et al.  Evaluation of a prime-boost vaccine schedule with distinct adenovirus vectors against malaria in rhesus monkeys. , 2009, Vaccine.

[13]  D. Montefiori,et al.  Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors. , 2009, Vaccine.

[14]  H. Ertl,et al.  New insights on adenovirus as vaccine vectors. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[15]  D. Mehrotra,et al.  Safety and Immunogenicity of the Merck Adenovirus Serotype 5 (MRKAd5) and MRKAd6 Human Immunodeficiency Virus Type 1 Trigene Vaccines Alone and in Combination in Healthy Adults , 2009, Clinical and Vaccine Immunology.

[16]  N. Sullivan,et al.  Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule , 2009, Nature Reviews Microbiology.

[17]  D. Montefiori,et al.  Immune Control of an SIV Challenge by a T Cell-Based Vaccine in Rhesus Monkeys , 2008, Nature.

[18]  N. Sullivan,et al.  Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule , 2009, Nature Reviews Microbiology.

[19]  Devan V Mehrotra,et al.  Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial , 2008, The Lancet.

[20]  V. A. Stewart,et al.  Adenovirus 5 and 35 vectors expressing Plasmodium falciparum circumsporozoite surface protein elicit potent antigen-specific cellular IFN-gamma and antibody responses in mice. , 2008, Vaccine.

[21]  K. Mansfield,et al.  Magnitude and Phenotype of Cellular Immune Responses Elicited by Recombinant Adenovirus Vectors and Heterologous Prime-Boost Regimens in Rhesus Monkeys , 2008, Journal of Virology.

[22]  M. Havenga,et al.  High-level expression from two independent expression cassettes in replication-incompetent adenovirus type 35 vector. , 2007, The Journal of general virology.

[23]  Rodrigo Lopez,et al.  Clustal W and Clustal X version 2.0 , 2007, Bioinform..

[24]  R. Koup,et al.  Myeloid and Plasmacytoid Dendritic Cells Are Susceptible to Recombinant Adenovirus Vectors and Stimulate Polyfunctional Memory T Cell Responses , 2007, The Journal of Immunology.

[25]  T. van der Poll,et al.  Protective Immune Responses to a Recombinant Adenovirus Type 35 Tuberculosis Vaccine in Two Mouse Strains: CD4 and CD8 T-Cell Epitope Mapping and Role of Gamma Interferon , 2007, Infection and Immunity.

[26]  N. Letvin,et al.  Effect of Preexisting Immunity to Adenovirus Human Serotype 5 Antigens on the Immune Responses of Nonhuman Primates to Vaccine Regimens Based on Human- or Chimpanzee-Derived Adenovirus Vectors , 2007, Journal of Virology.

[27]  K. Mansfield,et al.  Comparative Seroprevalence and Immunogenicity of Six Rare Serotype Recombinant Adenovirus Vaccine Vectors from Subgroups B and D , 2007, Journal of Virology.

[28]  G. Nabel,et al.  Mechanism of Ad5 Vaccine Immunity and Toxicity: Fiber Shaft Targeting of Dendritic Cells , 2007, PLoS pathogens.

[29]  J. Mascola,et al.  Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. , 2006, The Journal of infectious diseases.

[30]  M. Havenga,et al.  Immunogenicity of Heterologous Recombinant Adenovirus Prime-Boost Vaccine Regimens Is Enhanced by Circumventing Vector Cross-Reactivity , 2006, Journal of Virology.

[31]  T. D. de Gruijl,et al.  Intradermal Delivery of Adenoviral Type-35 Vectors Leads to High Efficiency Transduction of Mature, CD8+ T Cell-Stimulating Skin-Emigrated Dendritic Cells , 2006, The Journal of Immunology.

[32]  M. Havenga,et al.  Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells. , 2006, The Journal of general virology.

[33]  Laurie Lamoreaux,et al.  Amine reactive dyes: an effective tool to discriminate live and dead cells in polychromatic flow cytometry. , 2006, Journal of immunological methods.

[34]  R. Koup,et al.  Competing Interests: GJN: , 2022 .

[35]  B. Berkhout,et al.  Immunogenicity and Protection of a Recombinant Human Adenovirus Serotype 35-Based Malaria Vaccine against Plasmodium yoelii in Mice , 2006, Infection and Immunity.

[36]  J. Stockman.  A Large Outbreak of Acute Encephalitis With High Fatality Rate in Children in Andhra Pradesh, India, in 2003, Associated With Chandipura Virus , 2006 .

[37]  K. Mansfield,et al.  Immunogenicity of Recombinant Fiber-Chimeric Adenovirus Serotype 35 Vector-Based Vaccines in Mice and Rhesus Monkeys , 2005, Journal of Virology.

[38]  M. Lifton,et al.  Immunogenicity of Heterologous Prime-Boost Regimens Involving Recombinant Adenovirus Serotype 11 (Ad11) and Ad35 Vaccine Vectors in the Presence of Anti-Ad5 Immunity , 2005, Journal of Virology.

[39]  J. Mascola,et al.  Replication-Defective Adenovirus Serotype 5 Vectors Elicit Durable Cellular and Humoral Immune Responses in Nonhuman Primates , 2005, Journal of Virology.

[40]  V. Arankalle,et al.  A large outbreak of acute encephalitis with high fatality rate in children in Andhra Pradesh, India, in 2003, associated with Chandipura virus , 2004, The Lancet.

[41]  B. Berkhout,et al.  Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector , 2004, AIDS.

[42]  S. Kostense,et al.  Immunogenicity of Recombinant Adenovirus Serotype 35 Vaccine in the Presence of Pre-Existing Anti-Ad5 Immunity1 , 2004, The Journal of Immunology.

[43]  Jaap Goudsmit,et al.  Quantifying Adenovirus-Neutralizing Antibodies by Luciferase Transgene Detection: Addressing Preexisting Immunity to Vaccine and Gene Therapy Vectors , 2003, Journal of Clinical Microbiology.

[44]  R. Koup,et al.  Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates , 2003, Nature.

[45]  S. Kostense,et al.  Replication-Deficient Human Adenovirus Type 35 Vectors for Gene Transfer and Vaccination: Efficient Human Cell Infection and Bypass of Preexisting Adenovirus Immunity , 2003, Journal of Virology.

[46]  Henryk Mach,et al.  Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity , 2002, Nature.

[47]  A. Sanchez,et al.  Development of a preventive vaccine for Ebola virus infection in primates , 2000, Nature.

[48]  L. Rodriguez,et al.  Re-emergence of vesicular stomatitis in the western United States is associated with distinct viral genetic lineages. , 2000, Virology.

[49]  A. Houweling,et al.  Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. , 1996, Human gene therapy.

[50]  A. Rowan.  Guide for the Care and Use of Laboratory Animals , 1979 .

[51]  J. Maizel,et al.  The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. , 1974, Virology.